Pegmolesatide SC

PreclinicalPeptide

GGuangdong Provincial People's Hospital

Pegmolesatide SC is one of 33 small molecule programs targeting Chronic Kidney Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Kidney DiseaseActive, not recruiting

Chronic Kidney DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Aranesp

Amgen

Preclinical

40 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 3

Lorelco

Sanofi

Preclinical

1 4

Activase

Flomax

Genotropin

1 7

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

PROCRIT

WWim Janssens

Preclinical

1 9

Singulair

OOrganon and Co

Preclinical

—10

Ativan

BBausch Health Americas, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

Chronic Kidney Disease

NCT07136792

Clinical

Trials by Indication[1]

Chronic Kidney Disease1 trial

A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)

Recruiting·GGuangdong Provincial People's Hospital·N/A·NCT07136792·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pegmolesatide SC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pegmolesatide SC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pegmolesatide SC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangdong Provincial People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Preclinical[1]
Company: GGuangdong Provincial People's Hospital

Pegmolesatide SC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Chronic Kidney Disease1 trial

References

Drug Info

Quick Facts

Related News